Occult hepatitis B infection in patients infected with HIV: Report of two cases of hepatitis B reactivation and prevalence in a hospital cohort

Journal of Medical Virology

Volumn 82, Issue 2, 2010, Pages 206-212

  Bloquel, B ^a   Jeulin, H ^a,b   Burty, C ^a   Letranchant, L ^a   Rabaud, C ^a   Venard, V ^a,b  

^a CHU NANCY BRABOIS   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Hepatitis B viral load; Hepatitis B virus; Human immunodeficiency virus; Isolated anti HBc antibodies; Occult hepatitis

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; RITONAVIR; STAVUDINE; VIRUS DNA;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY ISOLATION; ANTIVIRAL RESISTANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CHILD; COHORT ANALYSIS; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PATIENT COMPLIANCE; SCHOOL CHILD; SEROPREVALENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VIRUS LOAD; VIRUS REACTIVATION; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; COHORT STUDIES; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HIV INFECTIONS; HOSPITALS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; VIRUS ACTIVATION; YOUNG ADULT;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 74549136677     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21685     Document Type: Article

References (35)

1. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, Reiss P, Thiebaut R, Weiland O, Yazdanpanah Y, Zeuzem S. 2005. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 42:615-624.
2. Bani-Sadr F, Palmer P, Scieux C, Molina JM. 2004. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis Bvirus. Clin Infect Dis 39:1062-1064.
3. Benhamou Y. 2007.Hepatitis B in the HIV-coinfected patient. J Acquir Immune Defic Syndr 45:S57-S65; discussion S57-S66.
4. Chamorro AJ, Casado JL, Bellido D, Moreno S. 2005. Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker. Eur J Clin Microbiol Infect Dis 24:492-494.
5. Chemin I, Trepo C. 2005. Clinical impact of occult HBV infections. J Clin Virol 34:S15-S21.
6. Clark SJ, Creighton S, Horner M, Smith HM, Portmann B, Taylor C, Cramp ME. 2006. Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression. Int J STD AIDS 17:67-69.
7. Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. 2009. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 81:441-445.
8. Datta S, Banerjee A, Chandra PK, Chowdhury A, Chakravarty R. 2006. Genotype, phylogenetic analysis, and transmission pattern of occult hepatitisBvirus (HBV) infection in families of asymptomatic HBsAg carriers. J Med Virol 78:53-59.
9. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. 1999. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 180:607-613.
10. Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, Nacca C, Sagnelli C, De Stefano G, Ferraro T, De Stefano C, Sagnelli E. 2006. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 20:1253-1260.
11. Gartner BC, Jung W, Welsch C, Fischinger J, Schubert J, Zeuzem S, Mueller-Lantzsch N, Wend UC, Gerlich WH. 2007. Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation. J Clin Virol 38:146-148.
12. Gutierrez S, Guillemi S, Jahnke N, Montessori V, Harrigan PR, Montaner JS. 2008. Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine. Clin Infect Dis 46:28-30.
13. Hino K, Basuni AA, Ireland J, Newell A, Mphahlele J, Smit EJ, Ngui SL, Teo CG, CarmanWF. 2002.Reappearance of hepatitisBsurface antigen in immunocompromised individuals: Reinfection or reactivation? Dig Dis Sci 47:415-418.
14. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M. 1998. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 17:6-13.
15. Kao JH, Chen PJ, Lai MY, Chen DS. 2002. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 40:4068-4071.
16. Lo Re,VIII, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, Tebas P, Stern J, Synnestvedt M, Localio AR, Kostman JR, Strom BL. 2007. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 44:315-320.
17. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. 2009. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol 81:406-412.
18. Manegold C, Hannoun C, Wywiol A, Dietrich M, Polywka S, Chiwakata CB, Gunther S. 2001. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 32:144-148.
19. Miailhes P, Trabaud MA, Pradat P, Lebouche B, Chevallier M, Chevallier P, Zoulim F, Trepo C. 2007. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: Relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 45:624-632.
20. Neau D, Winnock M, Jouvencel AC, Faure M, Castera L, Legrand E, Lacoste D, Ragnaud JM, Dupon M, Fleury H, Lafon ME, Dabis F. 2005. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis 40:750-753.
21. Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti AM. 2007. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol 79:1464-1471.
22. Nunez M, Rios P, Perez-Olmeda M, Soriano V. 2002. Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS 16:2099-2101.
23. Olinger CM, Jutavijittum P, Hubschen JM, Yousukh A, Samountry B, Thammavong T, Toriyama K, Muller CP. 2008. Possible new hepatitis B virus genotype, southeast Asia. Emerg Infect Dis 14: 1777-1780.
24. Olinger CM, Venard V, Njayou M, Oyefolu AO, Maiga I, Kemp AJ, Omilabu SA, le Faou A, Muller CP. 2006. Phylogenetic analysis of the precore/core gene of hepatitis B virus genotypes E and A in West Africa: New subtypes, mixed infections and recombinations. J Gen Virol 87:1163-1173.
25. Peters MG. 2007. Diagnosis and management of hepatitis B virus and HIV coinfection. Top HIV Med 15:163-166.
26. Piroth L, Binquet C, Vergne M, Minello A, Livry C, Bour JB, Buisson M, Duong M, Grappin M, Portier H, ChavanetP. 2002. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol 36:681-686.
27. Piroth L, Carrat F, Larrat S, Goderel I, Martha B, Payan C, Lunel-Fabiani F, Bani-Sadr F, Perronne C, Cacoub P, Pol S, Morand P. 2008. Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy. J Hepatol 49:892-898.
28. Puoti M, Torti C, Bruno R, Filice G, Carosi G. 2006. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 44:S65-S70.
29. Raffa G, Maimone S, Cargnel A, Santantonio T, Antonucci G, Massari M, Schiavini M, Caccamo G, Pollicino T, Raimondo G. 2007. Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS 21:2171-2175.
30. Raimondo G, Pollicino T, Cacciola I, Squadrito G. 2007.Occult hepatitis B virus infection. J Hepatol 46:160-170.
31. Santos EA, Yoshida CF, Rolla VC, Mendes JM, Vieira IF, Arabe J, Gomes SA. 2003. Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 22:92-98.
32. Schnepf N, Sellier P, Bendenoun M, Zini JM, Sanson-le Pors MJ, Mazeron MC. 2007. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. J Clin Virol 39:48-50.
33. Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, Staszewski S, Stuermer M. 2005. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother 56:1087-1093.
34. Thio CL. 2003. Hepatitis B in the human immunodeficiency virus-infected patient: Epidemiology, natural history, and treatment. Semin Liver Dis 23:125-136.
35. Toro C, Jimenez V, Rodriguez C, Del Romero J, Rodes B, Holguin A, Alvarez P, Garcia-Campello M, Gomez-Hernando C, Guelar A, Sheldon J, de Mendoza C, Simon A, Soriano V. 2006. Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain. J Med Virol 78:1599-1608.